A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March ...

Strawberries may modestly enhance processing speed and lower systolic blood pressure in older adults, but they do not ...

Cognition may be just one phase of intelligence—as AI evolves, thought itself begins to dissolve into something more fluid, ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...

Alzheimer’s is a progressive neurological disorder that affects memory, thinking, and behavior. It worsens over time, leading ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

clinical phase 1b/2a study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Karolinska Development's ownership in Umecrine ...

The science-backed supplement is a must for building strength and muscle, but is there an optimal time to take it?

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...